Cargando…
Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence‐base review
The evidence supporting therapy with imatinib for bleomycin‐induced pneumonitis (BIP) is equivocal. Further experience is needed to establish its role in BIP management. While it may be considered in the management of BIP, it is important to be mindful of the adverse effects including thrombocytopen...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856242/ https://www.ncbi.nlm.nih.gov/pubmed/27190613 http://dx.doi.org/10.1002/ccr3.549 |